BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding around 0.5% on Thursday.

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst's opinion to trust.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Here's a look at some of the top biotechnology stocks from several analysts, according to Benzinga Analyst Stock Ratings.

Vertex Pharmaceuticals Incorporated VRTX

Argus Research’s analyst Jasper Hellweg maintained a Buy rating on the company's stock on November 17, 2022, and raised the price target from $320 to $340. Hellweg sees around 6% upside in the stock and has an accuracy rate of 69%.

Barclays analyst Gena Wang reiterated an Overweight rating on the company's stock on October 28, 2022, and increased the price target from $307 to $313. Wang predicts the stock declining over 2% and has an accuracy rate of 61%.

Recent News: Vertex Pharmaceuticals, during October, reported better-than-expected Q3 results and raised 2022 product revenue guidance.

• Beam Therapeutics Inc. BEAM

• SVB Leerink analyst Mani Foroohar maintained an Outperform rating on the company’s stock on November 7, 2022, but lowered the price target from $82 to $81. Foroohar sees around 77% surge in the company’s stock and has an accuracy rate of 39%.
• Barclays analyst Gena Wang maintained an Equal-Weight rating on the company’s stock on August 10, 2022, and raised the price target from $38 to $60. Wang sees around 30% increase in Baidu’s stock and has an accuracy rate of 61%.
• Recent News: The company, last month, posted a wider quarterly loss.

BioNTech SE BNTX

• Morgan Stanley’s analyst Matthew Harrison reiterated an Equal-Weight rating on the company’s stock on November 8, 2022, and raised the price target from $194 to $203. This analyst sees over 19% rise in the stock and has an accuracy rate of just 52%.
• Goldman Sachs analyst Chris Shibutani maintained a Neutral rating on November 8, 2022, and lowered the price target from $200 to $177. Shibutani sees the stock rising around 4%, and has an accuracy rate of 69%.
• Recent News: BioNTech and Ryvu Therapeutics S.A. recently entered into a multi-target research collaboration consisting of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvu's STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Vir Biotechnology, Inc. VIR

• Needham’s analyst Joseph Stringer reiterated a Buy rating on the company’s stock on November 4, 2022, but slashed the price target from $35 to $32. This analyst sees over 18% rise in the stock and has an accuracy rate of just 53%.
• SVB Leerink’s analyst Roanna Ruiz maintained an Outperform rating on November 4, 2022, and raised the price target from $40 to $45. Ruiz sees the stock rising over 66%, but has an accuracy rate of only 22%.
• Recent News: Vir Biotechnology, last month, reported a year-over-year increase in Q3 EPS and revenue.